Victory Capital Management Inc. Increases Stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Key Points

• Victory Capital Management Inc. significantly increased its stake in Integra LifeSciences by 1,067.6%, owning approximately 147,982 shares valued at $3.25 million as of the latest SEC filing.
• Institutional investors currently hold 84.78% of Integra LifeSciences, indicating strong institutional confidence in the company.
• Wall Street analysts show mixed opinions, with price targets ranging from $12.00 to $26.00 and a consensus rating of "Hold" at a target price of $18.63.

Victory Capital Management Inc. boosted its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 1,067.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 147,982 shares of the life sciences company's stock after buying an additional 135,308 shares during the quarter. Victory Capital Management Inc. owned approximately 0.19% of Integra LifeSciences worth $3,254,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Principal Financial Group Inc. increased its position in Integra LifeSciences by 2.5% during the 1st quarter. Principal Financial Group Inc. now owns 433,924 shares of the life sciences company's stock valued at $9,542,000 after purchasing an additional 10,492 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Integra LifeSciences during the 1st quarter worth approximately $251,000. Norges Bank acquired a new stake in shares of Integra LifeSciences during the 4th quarter worth approximately $8,967,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Integra LifeSciences by 3.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock worth $872,000 after buying an additional 1,437 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of Integra LifeSciences by 3,595.1% during the 1st quarter. GAMMA Investing LLC now owns 23,353 shares of the life sciences company's stock worth $5,140,000 after buying an additional 22,721 shares during the period. Institutional investors and hedge funds own 84.78% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Wells Fargo & Company reduced their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. JMP Securities reduced their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Finally, Truist Financial cut their target price on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Four investment analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $18.63.

Integra LifeSciences Stock Up 8.4%

NASDAQ:IART traded up $1.04 during trading hours on Thursday, hitting $13.41. 759,744 shares of the company traded hands, compared to its average volume of 966,612. The company has a quick ratio of 0.72, a current ratio of 1.21 and a debt-to-equity ratio of 0.81. The firm's 50-day simple moving average is $12.59 and its 200-day simple moving average is $17.80. Integra LifeSciences Holdings Corporation has a one year low of $11.06 and a one year high of $27.13. The company has a market cap of $1.04 billion, a PE ratio of -35.18, a PEG ratio of 0.72 and a beta of 1.15.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.12% and a negative net margin of 1.78%. The firm's revenue for the quarter was down .6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.63 EPS. Equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.